1.Safety of Gastrointestinal Endoscopy in Korea: A Nationwide Survey and Population-Based Study
Yunho JUNG ; Jung-Wook KIM ; Jong Pil IM ; Yu Kyung CHO ; Tae Hee LEE ; Jae-Young JANG
Journal of Korean Medical Science 2022;37(4):e24-
Background:
Attention should be paid to endoscopy-related complications and safety-related accidents that may occur in the endoscopy unit. This study investigated the current status of complications associated with diagnostic and therapeutic endoscopy in Korea.
Methods:
A questionnaire survey on endoscopy-related complications was conducted in a total of 50 tertiary or general hospitals in Korea. The results were compared to the population-level claims data from the Health Insurance Review & Assessment Service (HIRA), which analyzed endoscopy procedures conducted in 2017 in Korea.
Results:
The incidences of bleeding associated with diagnostic and therapeutic esophagogastroduodenoscopy (EGD) and with diagnostic and therapeutic colonoscopy were 0.224% and 3.155% and 0.198% and 0.356%, respectively, in the 2017 HIRA claims data, compared to 0.012% and 1.857%, and 0.024% and 0.717%, in the 50 hospitals surveyed.The incidences of perforation associated with diagnostic and therapeutic EGD and with diagnostic and therapeutic colonoscopy were 0.023% and 0.613%, and 0.007% and 0.013%, respectively, in the 2017 HIRA claims data compared to 0.001% and 0.325%, and 0.017% and 0.206%, in the 50 hospitals surveyed. In the HIRA claims data, the incidence of bleeding/perforation after diagnostic colonoscopy in clinics, community hospitals, general hospitals, and tertiary hospitals was 0.129%/0.000%, 0.088%/0.004%, 0.262%/0.009%, and 0.479%/0.030% respectively, and the corresponding incidence of bleeding/perforation after therapeutic colonoscopy was 0.258%/0.004%, 0.401%/0.007%, 0.408%/0.024%, and 0.731%/0.055%.
Conclusion
The incidences of complications associated with diagnostic and therapeutic EGD or colonoscopy tended to increase with the hospital volume in Korea.
2.Updates on the Disinfection and Infection Control Process of the Accredited Endoscopy Unit
Jeong Eun SHIN ; Yunho JUNG ; Jeong Hoon LEE ; Byoung Kwan SON ; Jae Young JANG ; Hyung Keun KIM ; Byung Ik JANG ;
Clinical Endoscopy 2019;52(5):443-450
A thorough disinfection and infection control process associated with gastrointestinal endoscopy is highly important for the health and safety of the examinee and the medical staff involved in the procedure. Endoscopic reprocessing and disinfection are two of the most important steps in quality control of endoscopy. In 2019, the Korean Society of Gastrointestinal Endoscopy updated the Accreditation of Qualified Endoscopy Unit assessment items for these quality indicators. Assessment of disinfection and infection control comprises 28 mandatory items in the categories of disinfection education, pre-cleaning, cleaning, disinfection, rinsing, drying, reprocessing, storage, endoscopic accessories, water bottle and connectors, space/facilities, personal protective equipment, disinfection ledger, and regulations regarding infection control and disinfection. The updated Accreditation of Qualified Endoscopy Unit assessment items are useful for improving the quality of endoscopy by ensuring thorough inspection of endoscopic disinfection and infection control.
Accreditation
;
Disinfection
;
Education
;
Endoscopy
;
Endoscopy, Gastrointestinal
;
Humans
;
Infection Control
;
Medical Staff
;
Personal Protective Equipment
;
Quality Control
;
Social Control, Formal
;
Water
3.Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication.
Yu Mi LEE ; Kyu Chan HUH ; Soon Man YOON ; Byung Ik JANG ; Jeong Eun SHIN ; Hoon Sup KOO ; Yunho JUNG ; Sae Hee KIM ; Hee Seok MOON ; Seung Woo LEE
Gut and Liver 2016;10(2):250-254
BACKGROUND/AIMS: To determine the incidence and clinical characteristics of tuberculosis (TB) medication-associated Clostridium difficile infection. METHODS: This multicenter study included patients from eight tertiary hospitals enrolled from 2008 to 2013. A retrospective analysis was conducted to identify the clinical features of C. difficile infection in patients who received TB medication. RESULTS: C. difficile infection developed in 54 of the 19,080 patients prescribed TB medication, representing a total incidence of infection of 2.83 cases per 1,000 adults. Fifty-one of the 54 patients (94.4%) were treated with rifampin. The patients were usually treated with oral metronidazole, which produced improvement in 47 of the 54 patients (87%). Twenty-three patients clinically improved with continuous rifampin therapy for C. difficile infection. There were no significant differences in improvement between patients treated continuously (n=21) and patients in whom treatment was discontinued (n=26). CONCLUSIONS: The incidence of C. difficile infection after TB medication was not low considering the relatively low TB medication dosage compared to other antibiotics. It may not be always necessary to discontinue TB medication. Instead, decisions concerning discontinuation of TB medication should be based on TB status.
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Infective Agents/therapeutic use
;
Antibiotics, Antitubercular/*adverse effects
;
*Clostridium difficile
;
Enterocolitis, Pseudomembranous/chemically induced/drug therapy/*epidemiology
;
Female
;
Humans
;
Incidence
;
Male
;
Metronidazole/therapeutic use
;
Middle Aged
;
Retrospective Studies
;
Rifampin/*adverse effects
;
Treatment Outcome
;
Tuberculosis/*drug therapy
4.Mycobacterium bovis infection in a wild sow (Sus scrofa): the first case in Korea.
Bok Kyung KU ; Bo Young JEON ; Jae Myung KIM ; Young Boo JANG ; Yunho JANG ; So Yoon YU ; Jiro KIM ; Oun Kyung MOON ; Suk Chan JUNG ; Min Kwon LEE ; Tae Nam JEONG
Journal of Veterinary Science 2016;17(3):427-429
Mycobacterium (M.) bovis causes tuberculosis and has a broad host range, including humans, livestock, and wild animals. M. bovis infection of wild boar has been reported in several European countries. We report here the first case of M. bovis infection in a domesticated wild sow in Korea. Granulomatous and necrotizing lesions with small numbers of acid-fast bacilli were observed in nodules of the lung of wild sow. Furthermore, the M. bovis isolate from the wild sow had spoligotype SB0140 and a novel MIRU-VNTR allelic profile, which is not found in cattle and deer in Korea.
Animals
;
Animals, Wild
;
Cattle
;
Deer
;
Host Specificity
;
Humans
;
Korea*
;
Livestock
;
Lung
;
Mycobacterium bovis*
;
Mycobacterium*
;
Sus scrofa
;
Tuberculosis
5.Diode Laser—Can It Replace the Electrical Current Used in Endoscopic Submucosal Dissection? (with Video)
Yunho JUNG ; Gwang Ho BAIK ; Weon Jin KO ; Bong Min KO ; Seong Hwan KIM ; Jin Seok JANG ; Jae-Young JANG ; Wan-Sik LEE ; Young Kwan CHO ; Sun Gyo LIM ; Hee Seok MOON ; In Kyung YOO ; Joo Young CHO
Clinical Endoscopy 2021;54(4):555-562
Background/Aims:
A new medical fiber-guided diode laser system (FDLS) is expected to offer high-precision cutting with simultaneous hemostasis. Thus, this study aimed to evaluate the feasibility of using the 1,940-nm FDLS to perform endoscopic submucosal dissection (ESD) in the gastrointestinal tract of an animal model.
Methods:
In this prospective animal pilot study, gastric and colorectal ESD using the FDLS was performed in ex vivo and in vivo porcine models. The completeness of en bloc resection, the procedure time, intraprocedural bleeding, histological injuries to the muscularis propria (MP) layer, and perforation were assessed.
Results:
The en bloc resection and perforation rates in the ex vivo study were 100% (10/10) and 10% (1/10), respectively; those in the in vivo study were 100% (4/4) and 0% for gastric ESD and 100% (4/4) and 25% (1/4) for rectal ESD, respectively. Deep MP layer injuries tended to occur more frequently in the rectal than in the gastric ESD cases, and no intraprocedural bleeding occurred in either group.
Conclusions
The 1,940-nm FDLS was capable of yielding high en bloc resection rates without intraprocedural bleeding during gastric and colorectal ESD in animal models.
6.Diode Laser—Can It Replace the Electrical Current Used in Endoscopic Submucosal Dissection? (with Video)
Yunho JUNG ; Gwang Ho BAIK ; Weon Jin KO ; Bong Min KO ; Seong Hwan KIM ; Jin Seok JANG ; Jae-Young JANG ; Wan-Sik LEE ; Young Kwan CHO ; Sun Gyo LIM ; Hee Seok MOON ; In Kyung YOO ; Joo Young CHO
Clinical Endoscopy 2021;54(4):555-562
Background/Aims:
A new medical fiber-guided diode laser system (FDLS) is expected to offer high-precision cutting with simultaneous hemostasis. Thus, this study aimed to evaluate the feasibility of using the 1,940-nm FDLS to perform endoscopic submucosal dissection (ESD) in the gastrointestinal tract of an animal model.
Methods:
In this prospective animal pilot study, gastric and colorectal ESD using the FDLS was performed in ex vivo and in vivo porcine models. The completeness of en bloc resection, the procedure time, intraprocedural bleeding, histological injuries to the muscularis propria (MP) layer, and perforation were assessed.
Results:
The en bloc resection and perforation rates in the ex vivo study were 100% (10/10) and 10% (1/10), respectively; those in the in vivo study were 100% (4/4) and 0% for gastric ESD and 100% (4/4) and 25% (1/4) for rectal ESD, respectively. Deep MP layer injuries tended to occur more frequently in the rectal than in the gastric ESD cases, and no intraprocedural bleeding occurred in either group.
Conclusions
The 1,940-nm FDLS was capable of yielding high en bloc resection rates without intraprocedural bleeding during gastric and colorectal ESD in animal models.
7.Differences in the Prognosis according to the Periods of Diagnosis in Ulcerative Colitis.
Hyun Beom CHAE ; Yoon Suk JUNG ; Dong Il PARK ; Chang Kyun LEE ; Kyu Chan HUH ; Jeong Eun SHIN ; Jae Hak KIM ; You Sun KIM ; Yunho JUNG ; Sung Ae JUNG ; Hyun Ju SONG ; Hyun Joo JANG ; Sung Noh HONG ; Young Ho KIM
The Korean Journal of Gastroenterology 2014;64(2):93-97
BACKGROUND/AIMS: Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC. The aim of this study was to investigate the differences of medication use and prognosis in UC patients according to the periods of diagnosis. METHODS: From 1987 to 2012, a total of 1,422 patients with UC were retrospectively reviewed in 12 hospitals. The study population was divided into two groups according to the periods of diagnosis as follows; group A: 1987-2005, group B: 2006-2012. Analyzed variables were compared by using chi-square test and logistic regression analysis. RESULTS: Mean age of the subjects was 42.2 years, and the mean follow-up period was 4.7 years. In univariate analysis, the use of infliximab in group B was significantly higher than group A (4.5% vs. 7.6%, p=0.016), and UC-related hospitalization (45.8% vs. 40.1%, p=0.031) and UC-related surgery (6.4% vs. 3.5%, p=0.010) in group B was significantly lower than that of group A. The use of oral steroid in surgery group was significantly higher than non-surgery group in multivariate analysis (OR 1.85, 95% CI 1.03-3.30, p=0.039). CONCLUSIONS: Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.
Adult
;
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
;
Colitis, Ulcerative/*diagnosis/drug therapy/pathology
;
Female
;
Follow-Up Studies
;
Hospitalization
;
Humans
;
Infliximab/therapeutic use
;
Logistic Models
;
Male
;
Mesalamine/therapeutic use
;
Middle Aged
;
Odds Ratio
;
Prognosis
;
Retrospective Studies
;
Time Factors
8.Molecular and genomic features of Mycobacterium bovis strain 1595 isolated from Korean cattle.
Narae KIM ; Yunho JANG ; Jin Kyoung KIM ; Soyoon RYOO ; Ka Hee KWON ; Miso KIM ; Shin Seok KANG ; Hyeon Seop BYEON ; Hee Soo LEE ; Young Hee LIM ; Jae Myung KIM
Journal of Veterinary Science 2017;18(S1):333-341
The aim of this study was to investigate the molecular characteristics and to conduct a comparative genomic analysis of Mycobacterium (M.) bovis strain 1595 isolated from a native Korean cow. Molecular typing showed that M. bovis 1595 has spoligotype SB0140 with mycobacterial interspersed repetitive units-variable number of tandem repeats typing of 4-2-5-3-2-7-5-5-4-3-4-3-4-3, representing the most common type of M. bovis in Korea. The complete genome sequence of strain 1595 was determined by single-molecule real-time technology, which showed a genome of 4351712 bp in size with a 65.64% G + C content and 4358 protein-coding genes. Comparative genomic analysis with the genomes of Mycobacterium tuberculosis complex strains revealed that all genomes are similar in size and G + C content. Phylogenetic analysis revealed all strains were within a 0.1% average nucleotide identity value, and MUMmer analysis illustrated that all genomes showed positive collinearity with strain 1595. A sequence comparison based on BLASTP analysis showed that M. bovis AF2122/97 was the strain with the greatest number of completely matched proteins to M. bovis 1595. This genome sequence analysis will serve as a valuable reference for improving understanding of the virulence and epidemiologic traits among M. bovis isolates in Korea.
Animals
;
Cattle*
;
Genome
;
Genomics
;
Korea
;
Molecular Typing
;
Mycobacterium bovis*
;
Mycobacterium tuberculosis
;
Mycobacterium*
;
Sequence Analysis
;
Tandem Repeat Sequences
;
Virulence
9.Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).
Eun Soo KIM ; Kyeong Ok KIM ; Byung Ik JANG ; Chang Kyun LEE ; Hyo Jong KIM ; Kang Moon LEE ; You Sun KIM ; Chang Soo EUN ; Sung Ae JUNG ; Suk Kyun YANG ; Jun LEE ; Tae Oh KIM ; Yunho JUNG ; Geom Seog SEO ; Soon Man YOON
Gut and Liver 2016;10(3):391-398
BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. METHODS: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. RESULTS: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was ‘doctor's presence' (68.3%, 82/120), and ADA was “easy to use” (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. CONCLUSIONS: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor's presence might be the main contributing factor for this decision.
Crohn Disease*
;
Humans
;
Korea
;
Logistic Models
;
Male
;
Necrosis*
;
Patient Preference
;
Prospective Studies
;
Tertiary Care Centers
10.National Endoscopy Quality Improvement Program Remains Suboptimal in Korea.
Jae Myung CHA ; Jeong Seop MOON ; Il Kwun CHUNG ; Jin Oh KIM ; Jong Pil IM ; Yu Kyung CHO ; Hyun Gun KIM ; Sang Kil LEE ; Hang Lak LEE ; Jae Young JANG ; Eun Sun KIM ; Yunho JUNG ; Chang Mo MOON ; Yeol KIM ; Bo Young PARK
Gut and Liver 2016;10(5):699-705
BACKGROUND/AIMS: We evaluated the characteristics of the National Cancer Screening Program (NCSP) and opinions regarding the National Endoscopy Quality Improvement Program (NEQIP). METHODS: We surveyed physicians performing esophagogastroduodenoscopy and/or colonoscopy screenings as part of the NCSP via e-mail between July and August in 2015. The 32-item survey instrument included endoscopic capacity, sedation, and reprocessing of endoscopes as well as opinions regarding the NEQIP. RESULTS: A total of 507 respondents were analyzed after the exclusion of 40 incomplete answers. Under the current capacity of the NCSP, the typical waiting time for screening endoscopy was less than 4 weeks in more than 90% of endoscopy units. Performance of endoscopy reprocessing was suboptimal, with 28% of respondents using unapproved disinfectants or not knowing the main ingredient of their disinfectants and 15% to 17% of respondents not following reprocessing protocols. Agreement with the NEQIP was optimal, because only 5.7% of respondents did not agree with NEQIP; however, familiarity with the NEQIP was suboptimal, because only 37.3% of respondents were familiar with the NEQIP criteria. CONCLUSIONS: The NEQ-IP remains suboptimal in Korea. Given the suboptimal performance of endoscopy reprocessing and low familiarity with the NEQIP, improved quality in endoscopy reprocessing and better understanding of the NEQIP should be emphasized in Korea.
Colonoscopy
;
Colorectal Neoplasms
;
Disinfectants
;
Early Detection of Cancer
;
Electronic Mail
;
Endoscopes
;
Endoscopy*
;
Endoscopy, Digestive System
;
Korea*
;
Mass Screening
;
Quality Improvement*
;
Recognition (Psychology)
;
Stomach Neoplasms
;
Surveys and Questionnaires